The latest results from Avrobio's gene therapy trial saw its stock drop by 52%, as the treatment's efficacy is questioned. Shares of Avrocor fell more than 6% in after-hours trading on Tuesday. With the data suggesting the benefits of the treatment do not last over time and would need to be repeated regularly, millions of dollars in market capitalisation disappeared as investors withdrew.
The latest results from Avrobio's gene therapy trial saw its stock drop by 52%, as the treatment's efficacy is questioned. In an update on the company's Fabry disease-fighting gene therapy trial, vector copy number in patients' peripheral blood, a key indicator for the transfer of healthy genes to cells, saw drops in four out of four cases post-treatment. With the data suggesting the benefits of the treatment do not last over time and would need to be repeated regularly, millions of dollars in market capitalisation disappeared as investors withdrew.